Details
Stereochemistry | RACEMIC |
Molecular Formula | C20H27N.ClH |
Molecular Weight | 317.896 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC(CC(C1=CC=CC=C1)C2=CC=CC=C2)NC(C)(C)C
InChI
InChIKey=RNGHAJVBYQPLAZ-UHFFFAOYSA-N
InChI=1S/C20H27N.ClH/c1-16(21-20(2,3)4)15-19(17-11-7-5-8-12-17)18-13-9-6-10-14-18;/h5-14,16,19,21H,15H2,1-4H3;1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C20H27N |
Molecular Weight | 281.4351 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Terodiline is a racemic compound, and its main indication was detrusor instability syndrome. With effects on detrusor muscles, terodiline was used for bladder incontinence. Terodiline has both anticholinergic and calcium antagonist properties and, as a result, effectively reduces abnormal bladder contractions caused by detrusor instability. When administered to adult patients with urge incontinence (generally as a 25mg twice-daily dose) terodiline reduces diurnal and nocturnal micturition frequency and incontinence episodes. The (R)-enantiomer of terodiline (R(+)-terodiline) can trigger cardiovascular toxicities, such as LQTS and TdP, which led to its withdrawal in 1991. Terodiline under the brand name Micturin was licensed and marketed in the United
Kingdom, in 1986, for the management of a specific
form of urinary incontinence, detrusor instability.
It was eventually marketed in 20 other countries,
mainly in Europe and Japan, but not the United
States of America.
CNS Activity
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Safety profile of tolterodine as used in general practice in England: results of prescription-event monitoring. | 2001 |
|
Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog. | 2001 Aug-Sep |
|
The relationship of clinical QT prolongation to outcome in the conscious dog using a beat-to-beat QT-RR interval assessment. | 2002 Aug |
|
Effect of muscarinic antagonists on micturition pressure measured by cystometry in normal, conscious rats. | 2002 Jun |
|
Contact guidance induced organization of extracellular matrix. | 2004 Aug |
|
Assessing QT prolongation in conscious dogs: validation of a beat-to-beat method. | 2008 May |
|
Stereoselective Inhibition of the hERG1 Potassium Channel. | 2010 |
|
Identification of human Ether-à-go-go related gene modulators by three screening platforms in an academic drug-discovery setting. | 2010 Dec |
|
New insights into molecular targets for urinary incontinence. | 2010 Oct |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2292235
When administered to adult patients with urge incontinence (generally as a 25mg twice-daily dose) terodiline reduces diurnal and nocturnal micturition frequency and incontinence episodes.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10334509
Terodiline reduced outward I(K1) with an IC50 of 7 uM in guinea pig ventricular myocytes; maximal reduction was 60% with 100-300 uM concentration. Inhibition was independent of current direction, and persisted after removal of the drug. Terodiline (3-5 uM) lengthened action potentials in guinea pig papillary muscles by ca.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:58:23 GMT 2023
by
admin
on
Fri Dec 15 17:58:23 GMT 2023
|
Record UNII |
K2ZA89W43F
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29696
Created by
admin on Fri Dec 15 17:58:24 GMT 2023 , Edited by admin on Fri Dec 15 17:58:24 GMT 2023
|
||
|
NCI_THESAURUS |
C29698
Created by
admin on Fri Dec 15 17:58:24 GMT 2023 , Edited by admin on Fri Dec 15 17:58:24 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m954
Created by
admin on Fri Dec 15 17:58:24 GMT 2023 , Edited by admin on Fri Dec 15 17:58:24 GMT 2023
|
PRIMARY | Merck Index | ||
|
K2ZA89W43F
Created by
admin on Fri Dec 15 17:58:24 GMT 2023 , Edited by admin on Fri Dec 15 17:58:24 GMT 2023
|
PRIMARY | |||
|
7082-21-5
Created by
admin on Fri Dec 15 17:58:24 GMT 2023 , Edited by admin on Fri Dec 15 17:58:24 GMT 2023
|
PRIMARY | |||
|
CHEMBL363295
Created by
admin on Fri Dec 15 17:58:24 GMT 2023 , Edited by admin on Fri Dec 15 17:58:24 GMT 2023
|
PRIMARY | |||
|
DTXSID1048968
Created by
admin on Fri Dec 15 17:58:24 GMT 2023 , Edited by admin on Fri Dec 15 17:58:24 GMT 2023
|
PRIMARY | |||
|
23479
Created by
admin on Fri Dec 15 17:58:24 GMT 2023 , Edited by admin on Fri Dec 15 17:58:24 GMT 2023
|
PRIMARY | |||
|
235839
Created by
admin on Fri Dec 15 17:58:24 GMT 2023 , Edited by admin on Fri Dec 15 17:58:24 GMT 2023
|
PRIMARY | RxNorm | ||
|
C152570
Created by
admin on Fri Dec 15 17:58:24 GMT 2023 , Edited by admin on Fri Dec 15 17:58:24 GMT 2023
|
PRIMARY | |||
|
SUB04728MIG
Created by
admin on Fri Dec 15 17:58:24 GMT 2023 , Edited by admin on Fri Dec 15 17:58:24 GMT 2023
|
PRIMARY | |||
|
100000084814
Created by
admin on Fri Dec 15 17:58:24 GMT 2023 , Edited by admin on Fri Dec 15 17:58:24 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |